BRTX-100 + Saline
Phase 2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lumbar Disc Disease
Conditions
Lumbar Disc Disease
Trial Timeline
Jun 30, 2022 → Dec 1, 2027
NCT ID
NCT04042844About BRTX-100 + Saline
BRTX-100 + Saline is a phase 2 stage product being developed by BioRestorative Therapies for Lumbar Disc Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04042844. Target conditions include Lumbar Disc Disease.
What happened to similar drugs?
2 of 2 similar drugs in Lumbar Disc Disease were approved
Approved (2) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
12
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04042844 | Phase 2 | Recruiting |
Competing Products
4 competing products in Lumbar Disc Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| teriparatide + Placebo | Eli Lilly | Approved | 43 |
| Pregabalin + Diphenhydramine | Pfizer | Approved | 43 |
| BG00010 IV + BG00010 SC + Placebo IV + Placebo SC | Biogen | Phase 1 | 26 |
| BG00010 + Placebo | Biogen | Phase 2 | 32 |